338 related articles for article (PubMed ID: 33289297)
41. Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i.
Blonde L; Fainberg U; Kaltoft MS; Mosenzon O; Ramesh C; Rea R
Diabetes Obes Metab; 2021 Oct; 23(10):2234-2241. PubMed ID: 34132018
[TBL] [Abstract][Full Text] [Related]
42. SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks.
Taylor SI; Blau JE; Rother KI; Beitelshees AL
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):949-958. PubMed ID: 31585721
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of sotagliflozin in treating diabetes type 1.
Rendell MS
Expert Opin Pharmacother; 2018 Feb; 19(3):307-315. PubMed ID: 29212386
[TBL] [Abstract][Full Text] [Related]
44. SGLT inhibition: a possible adjunctive treatment for type 1 diabetes.
Akturk HK; Rewers A; Garg SK
Curr Opin Endocrinol Diabetes Obes; 2018 Aug; 25(4):246-250. PubMed ID: 29794497
[TBL] [Abstract][Full Text] [Related]
45. Effects of Concomitant Administration of Sodium Glucose Co-transporter 2 Inhibitor with Insulin on Hemoglobin A1c, Body Mass Index and Serum Lipid Profile in Japanese Type 2 Diabetic Patients.
Kusunoki M; Natsume Y; Miyata T; Tsutsumi K; Oshida Y
Drug Res (Stuttg); 2018 Dec; 68(12):669-672. PubMed ID: 29966150
[TBL] [Abstract][Full Text] [Related]
46. Sotagliflozin as a potential treatment for type 2 diabetes mellitus.
Cariou B; Charbonnel B
Expert Opin Investig Drugs; 2015; 24(12):1647-56. PubMed ID: 26548423
[TBL] [Abstract][Full Text] [Related]
47. THE EMERGING ROLE OF ADJUNCTIVE NONINSULIN ANTIHYPERGLYCEMIC THERAPY IN THE MANAGEMENT OF TYPE 1 DIABETES.
Bode BW; Garg SK
Endocr Pract; 2016 Feb; 22(2):220-30. PubMed ID: 26484403
[TBL] [Abstract][Full Text] [Related]
48. Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone.
Danne T; Joish VN; Afonso M; Banks P; Sawhney S; Lapuerta P; Davies MJ; Buse JB; Lin D; Reaney M; Guillonneau S; Snoek FJ; Bailey TS; Polonsky WH
Diabetes Technol Ther; 2021 Jan; 23(1):70-77. PubMed ID: 32721228
[No Abstract] [Full Text] [Related]
49. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes.
Philis-Tsimikas A; Billings LK; Busch R; Portillo CM; Sahay R; Halladin N; Eggert S; Begtrup K; Harris S
Diabetes Obes Metab; 2019 Jun; 21(6):1399-1408. PubMed ID: 30761720
[TBL] [Abstract][Full Text] [Related]
50. Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol.
Goldenberg RM; Gilbert JD; Hramiak IM; Woo VC; Zinman B
Diabetes Obes Metab; 2019 Oct; 21(10):2192-2202. PubMed ID: 31183975
[TBL] [Abstract][Full Text] [Related]
51. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
Ludvik B; Frías JP; Tinahones FJ; Wainstein J; Jiang H; Robertson KE; García-Pérez LE; Woodward DB; Milicevic Z
Lancet Diabetes Endocrinol; 2018 May; 6(5):370-381. PubMed ID: 29483060
[TBL] [Abstract][Full Text] [Related]
52. Sodium-glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials.
Rao L; Ren C; Luo S; Huang C; Li X
Acta Diabetol; 2021 Jul; 58(7):869-880. PubMed ID: 33651228
[TBL] [Abstract][Full Text] [Related]
53. SGLT inhibitor adjunct therapy in type 1 diabetes.
McCrimmon RJ; Henry RR
Diabetologia; 2018 Oct; 61(10):2126-2133. PubMed ID: 30132030
[TBL] [Abstract][Full Text] [Related]
54. Sotagliflozin: a combined SGLT1/SGLT2 inhibitor to treat diabetes.
Rendell MS
Expert Rev Endocrinol Metab; 2018 Nov; 13(6):333-339. PubMed ID: 30379091
[TBL] [Abstract][Full Text] [Related]
55. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Lapuerta P; Zambrowicz B; Strumph P; Sands A
Diab Vasc Dis Res; 2015 Mar; 12(2):101-10. PubMed ID: 25690134
[TBL] [Abstract][Full Text] [Related]
56. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Henry RR; Rosenstock J; Edelman S; Mudaliar S; Chalamandaris AG; Kasichayanula S; Bogle A; Iqbal N; List J; Griffen SC
Diabetes Care; 2015 Mar; 38(3):412-9. PubMed ID: 25271207
[TBL] [Abstract][Full Text] [Related]
57. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
[TBL] [Abstract][Full Text] [Related]
58. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC;
Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456
[TBL] [Abstract][Full Text] [Related]
59. Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial.
Blonde L; Belousova L; Fainberg U; Garcia-Hernandez PA; Jain SM; Kaltoft MS; Mosenzon O; Nafach J; Palle MS; Rea R
Diabetes Obes Metab; 2020 Jun; 22(6):929-937. PubMed ID: 31984646
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and Safety of SGLT2 Inhibitors in Type 1 Diabetes After the Introduction of an Off-Label Use Protocol for Clinical Practice.
Bayona Cebada A; Nattero-Chávez L; Alonso Díaz S; Escobar-Morreale HF; Luque-Ramírez M
Diabetes Technol Ther; 2020 Mar; 22(3):208-215. PubMed ID: 31644310
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
